STOCK TITAN

CureVac Announces Voting Results of General Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

CureVac N.V. (NASDAQ:CVAC) announced the results of its annual general meeting where shareholders approved most proposals, notably the appointments of Antony Blanc and Klaus Edvardsen as managing directors, and the re-appointment of Pierre Kemula. However, they rejected the authorization for the management board to acquire shares. The company emphasizes its focus on mRNA technology, leveraging over 20 years of expertise to develop innovative therapies across various domains.

Positive
  • Shareholders approved the appointments of Antony Blanc and Klaus Edvardsen as managing directors.
  • Re-appointment of Pierre Kemula as managing director received shareholder approval.
  • Adjustments to supervisory board compensation were approved.
Negative
  • Shareholder rejection of the management board's proposal to acquire shares.

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 25, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.

The shareholders of the Company voted in favour of all proposals, except for agenda item 13 relating to the authorization of the management board to acquire shares (or depositary receipts for shares) in the Company's capital. The proposals voted in favour for included the appointments of Antony Blanc and Klaus Edvardsen as managing directors, the re-appointment of Pierre Kemula as managing director and adjustments to the compensation of the supervisory board. A table containing tabulations of the votes casted is expected to be released in the coming days.

About CureVac
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

CureVac Media Contact
Anna Kamilli, Manager Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1684
anna.kamilli@curevac.com

Bettina Jödicke-Braas, Manager Communications
CureVac, Tübingen, Germany
T: 49 7071 9883-1087
bettina.joedicke-braas@curevac.com

Forward-Looking Statements

This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

SOURCE: CureVac



View source version on accesswire.com:
https://www.accesswire.com/653083/CureVac-Announces-Voting-Results-of-General-Meeting

FAQ

What were the voting results of CureVac's annual general meeting on June 25, 2021?

Most proposals were approved, including appointments of new managing directors, but the proposal to authorize share acquisitions was rejected.

Who were appointed as managing directors during the CureVac meeting?

Antony Blanc and Klaus Edvardsen were appointed as managing directors, while Pierre Kemula was re-appointed.

What proposal did shareholders reject at CureVac's annual general meeting?

Shareholders rejected the authorization for the management board to acquire shares.

What is CureVac's focus in the biopharmaceutical industry?

CureVac focuses on developing transformative medicines using messenger RNA (mRNA) technology.

CureVac N.V. Ordinary Shares

NASDAQ:CVAC

CVAC Rankings

CVAC Latest News

CVAC Stock Data

671.89M
122.80M
45.26%
18.87%
1.97%
Biotechnology
Healthcare
Link
United States of America
Tübingen